KLH-conjugated synthetic peptide encompassing a sequence within the center region of human LILRB.
Conjugation:
Unconjugated
Alternative Names:
ILT2, LIR1, MIR7, Leukocyte immunoglobulin-like receptor subfamily B member 1, LIR-1, Leukocyte immunoglobulin-like receptor 1, CD85 antigen-like family member J, Immunoglobulin-like transcript 2, ILT-2, Monocyte/macrophage immunoglobulin-like receptor 7, MIR-7, CD85j
The leukocyte Ig-like receptor subfamily B (LILRB) are type-I transmembrane glycoproteins containing ligand-binding extracellular IgG-like domains and immunoreceptor tyrosine-based inhibition motifs (ITIMS) within the cytoplasmic domain, which recruit SHP protein tyrosine phosphatases, leading to transduction of signals that inhibit immune cell activation. Encoded within a region of chromosome 19 known as the leukocyte receptor complex, the LILRB subfamily of inhibitory receptors consists of LILRB1 to LILRB5, also referred to as CD85J, CD85D, CD85A, CD85K, and CD85C, respectively. There is mounting evidence that LILRBs function, in part, as a novel class of immune checkpoint receptors and support tumor growth through the transmission of inhibitory signals upon engagement of ligands expressed on tumor cells.
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Form:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Application Dilute:
WB: 1:500~1:1000 IF/ICC: 1:50~1:200
Application Notes:
LILRB polyclonal antibody detects endogenous levels of LILRB protein.
* VAT and and shipping costs not included. Errors and price changes excepted
